Anti‐inflammatory effects of serotonin 5‐HT 2A receptor activation in ovalbumin‐induced allergic asthma models
Thomas W. Flanagan, Melaine N. Sebastian, Charles D. Nichols
The FASEB Journal April 1, 2017 DOI: 10.1096/fasebj.31.1_supplement.820.4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Rodents (mice) in an ovalbumin-induced asthma model |
| Intervention | psilocybin |
| Topics | Serotonin |
| Keywords | Ovalbumin Asthma 5-HT Receptor Immunology Allergic inflammation Pharmacology |
| Citations | 2 |
| Key findings | Administration of the 5-HT2A receptor agonist (R)-DOI attenuates elevated airway hyperresponsiveness in a chronic mouse model of allergic asthma. |
Abstract
Only recently has the full therapeutic value of serotonin [5‐hydroxytryptophan (5‐HT)] receptor activation begun to be explored. Currently there are two 5‐HT 2A receptor agonists in human clinical trials for the treatment of depression and obesity. An exciting new therapeutic avenue in which 5‐HT 2A agonists might be employed is the modulation of inflammation in allergic airways disease. Our lab has previously used an ovalbumin (OVA)‐induced asthma model to demonstrate that administration of (R)‐2,5‐dimethoxy‐4‐iodoamphetamine [(R)‐DOI] prior to allergen challenge prevents many of the symptoms of allergic asthma. Here we have utilized a modified protocol to test the effectiveness of (R)‐DOI in treating persistent allergic asthma. We demonstrate that administration of (R)‐DOI in a chronic model attenuates the elevated airway hyperresponsiveness (AHR) typically observed in an asthmatic response. We also have probed for the expression of inflammatory markers in the lung and BALF. We concurrently are testing for the impact psilocybin and other tryptamines have on AHR in rodents using our OVA model. Overall our strategy is to develop 5‐HT 2A receptor agonism as a viable treatment modality against asthma and other inflammatory disorders. Support or Funding Information American Asthma Foundation Scholar Grant Award
Comparable studies
Other preclinical and animal studies on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Mice | 2021 | Observational cohort | |
| Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Rats (implied by typical neurochemical study context) | 1987 | Experimental study | |
| Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors In vitro and in vivo (rodent) models | 2023 | Experimental study | |
| 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Rat brain | 1987 | Animal experiment | |
| Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells | 2006 | In vitro laboratory study |